XBiotech Inc. (XBIT)
NMS · Healthcare · Biotechnology
$2.19
+0.92%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$66.8M
Shares Outstanding
30.5M
Exchange
NMS
Currency
USD
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.0M) | (29.8M) | (6.3M) | (6.1M) |
| Net Income | (6.0M) | (26.9M) | (5.5M) | (6.7M) |
| Diluted EPS | $-0.20 | N/A | $-0.18 | $-0.22 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 4.0M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.4M | 0.00 | ||
| Operating Income | (34.5M) | (37.5M) | (42.5M) | (55.7M) |
| Net Income | (32.9M) | (24.6M) | (38.5M) | (45.5M) |
| Diluted EPS | $-1.08 | $-0.81 | $-1.26 | $-1.49 |